Evaluating the clinical trends and benefits of low-dose computed tomography in lung cancer patients.

ABSTRACT:

Background

Despite guideline recommendations, utilization of low-dose computed tomography (LDCT) for lung cancer screening remains low. The driving factors behind these low rates and the real-world effect of LDCT utilization on lung cancer outcomes remain limited.

Methods

We identified patients diagnosed with non-small cell lung cancer (NSCLC) from 2015 to 2017 within the Veterans Health Administration. Multivariable logistic regression assessed the influence of LDCT screening on stage at diagnosis. Lead time correction using published LDCT lead times was performed. Cancer-specific mortality (CSM) was evaluated using Fine-Gray regression with non-cancer death as a competing risk. A lasso machine learning model identified important predictors for receiving LDCT screening.

SUBMITTER: Qiao EM 

PROVIDER: S-EPMC8525167 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature